Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pralidoxime→

Pralidoxime Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
51-15-0
Molecular formula
C7H9ClN2O
Molecular weight
172.61 g/mol
Drug class
Cholinesterase Reactivator
Mechanism of action
Cholinesterase Reactivators
Indications / reported uses
  • Poisoning
  • Drug Overdose
  • Drug-Related Side Effects and Adverse Reactions
View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pralidoxime Environmental Risk Assessment (ERA) (the Pralidoxime ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.